http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2012200798-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_999c840a6fed942b465649749cd60d18 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55 |
filingDate | 2012-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e08f1c829a667a55f4a8a8f4503b418c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_717c68138b76b9bf76fbd19e42cd7cc2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b49cf73bafee95e019997a7891d3d61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d771bb56c0aad9961640ca50daa2dd50 |
publicationDate | 2012-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2012200798-A1 |
titleOfInvention | Compounds for enzyme inhibition |
abstract | Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) 5 hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. |
priorityDate | 2005-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 802.